JESSICA BANKS: Open Payments
NPI 1336870765 · LA FAYETTE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,084 in 60 payments from 16 companies in 2025. Trend: 2023 $580 · 2024 $569 · 2025 $1,084
Food & beverage: $1,084
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $272 |
| Novo Nordisk Inc | 9 | $146 |
| Lilly USA, LLC | 10 | $140 |
| Otsuka America Pharmaceutical, Inc. | 4 | $82 |
| Sumitomo Pharma America, Inc. | 4 | $77 |
| PFIZER INC. | 4 | $72 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $52 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
Products named: VRAYLAR, Ozempic, REXULTI, QULIPTA, GEMTESA, JARDIANCE, MOUNJARO, Kerendia.
Industry payments across GA — which companies pay providers there.
